Nasrallah, H.
601  Ergebnisse:
Personensuche X
?
1

P.577 ADVANCE: phase 2, randomised, double-blind, placebo-c..:

Bugarski-Kirola, D. ; Arango, C. ; Fava, M....
European Neuropsychopharmacology.  40 (2020)  - p. S328-S329 , 2020
 
?
2

Early metabolic and mitochondrial remodeling in a pig model..:

Pasdois, P. ; Nasrallah, H. ; Kuiper, M....
Archives of Cardiovascular Diseases Supplements.  9 (2017)  2 - p. 162 , 2017
 
?
3

Cariprazine for negative symptoms of schizophrenia: pooled ..:

Durgam, S. ; Earley, W. ; Lu, K....
European Neuropsychopharmacology.  26 (2016)  - p. S552 , 2016
 
?
6

C.08.02 Are psychotic events neurotoxic?:

Nasrallah, H.
European Neuropsychopharmacology.  24 (2014)  - p. S757-S758 , 2014
 
?
7

P.3.d.025 Safety and tolerability of cariprazine in long-te..:

Nasrallah, H.A. ; Cutler, A.J. ; Wang, Y....
European Neuropsychopharmacology.  24 (2014)  - p. S536 , 2014
 
?
 
?
 
?
 
?
12

Beyond the facts in schizophrenia: closing the gaps in diag..:

Nasrallah, H. ; Tandon, R. ; Keshavan, M.
Epidemiology and Psychiatric Sciences.  20 (2011)  4 - p. 317-327 , 2011
 
?
13

Linkage analysis of schizophrenia in African-American famil..:

Wiener, H.W. ; Klei, L. ; Irvin, M.D....
Schizophrenia Research.  109 (2009)  1-3 - p. 70-79 , 2009
 
?
14

Symmetry of standing waves generated by a point defect in e..:

Simon, L. ; Bena, C. ; Vonau, F....
The European Physical Journal B.  69 (2009)  3 - p. 351-355 , 2009
 
?
15

Editorial Board:

NASRALLAH, H.A. ; DELISI, L.E.
Schizophrenia Research.  102 (2008)  1-3 - p. iii , 2008
 
1-15